Replies to post #150609 on Biotech Values

[biomaven0]

Presumably they could co-formulate as a BID pill. But agreed on the multiplicity of drugs upping the potential for DDIs (especially with ritonavir as part of the cocktail).

Peter

[DewDiligence]

It won't be 10 pills per day; at a minimum, ABT-450 will be co-formulated with ritonavir, which gets the count down to 8.

In any case, if ribavirin remains in the cocktail, BID dosing is probably preferable to qD dosing for tolerability reasons.

[oc631]

DDI+


Another issue with ABT's multi drug combo is how to treat failures.

A nuke based combo appears to need another class of drug (outside of ribavirin) to be effective in GT1 patients. Could patients failing to achieve a SVR using ABT's combo develop resistance to one or more partnering classes thus reduce their chances of achieving a SVR under second-line nuke-based or interferon-based therapy?

If a treatment-naive patient fails a nuke/NS5A combo it's safe to say they can be retreated in the future with a nuke/P.I. without concerns over class resistance.